Who is the CEO of ST Pharm?

According to the DART company overview, ST Pharm's representative director is Sung Moo-je (name as registered in Korean). The company was founded on 2008-08-18.

Where is ST Pharm listed?

ST Pharm trades on the Korea Exchange KOSDAQ market under the ticker 237690. Its fiscal year ends in December.

Does ST Pharm pay a dividend?

Yes. For fiscal 2025, ST Pharm paid a cash dividend of ₩500 per common share, a 0.3% yield as stated in its annual report, with a payout ratio of 18.3%. The prior year's dividend was ₩500.

Does ST Pharm have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Revenue +30% (latest quarterly revenue up more than 30% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); Clinical trial filing (filing on clinical trial plans or results (90 days)). These are factual flags, not investment advice.

Which companies are in the same industry as ST Pharm?

Under the Korean Standard Industrial Classification recorded on DART, ST Pharm is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

ST Pharm KRX:237690KOSDAQ

에스티팜 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h2

Articles, 7 days33

DART filings, 7 days2

Articles tracked132since Sep 11

In Q2 2026, ST Pharm reported revenue of ₩108bn, up 58.9% year on year, and operating profit of ₩18.3bn. ST Pharm (에스티팜) appeared in 33 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Oct 27 with 25 articles. The most common catalyst was earnings (12). It was most often mentioned alongside Dong-A Socio Holdings, Dong-a ST and SK biopharmaceuticals.

Filing signals Revenue +30% Revenue & profit growth Clinical trial filing Share pledge Screener

ST Pharm quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩108bn	+58.9%	₩18.3bn margin 16.9%	₩13.2bn
Q1 2026	₩67.0bn	+27.7%	₩11.5bn margin 17.2%	₩15.2bn
Q4 2025 derived	₩129bn	+11.5%	₩26.3bn margin 20.3%	₩31.0bn
Q3 2025	₩81.9bn	+32.7%	₩14.7bn margin 18.0%	₩17.5bn
Q2 2025	₩68.3bn	+53.1%	₩12.9bn margin 18.9%	₩5.4bn
Q1 2025	₩52.4bn	+1.4%	₩1.0bn margin 2.0%	₩709m
Q4 2024 derived	₩116bn	-4.1%	₩22.8bn margin 19.7%	₩12.4bn
Q3 2024	₩61.7bn	+10.3%	₩6.1bn margin 9.9%	₩13.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

ST Pharm top stories 2 weeks, by number of outlets

1
에스티팜, 3분기 매출 976억…전년比 19.1% 증가
3 outlets · 3 articlesFirst report Oct 27 12:37 뉴스1Earnings
2
에스티팜, 3분기 매출 976억원…올리고 상업화 매출 성장 견인
2 outlets · 2 articlesFirst report Oct 27 12:11 메디파나뉴스
3
에스티팜 3분기 영업이익 157억원…작년 동기 대비 6.6%↑
2 outlets · 2 articlesFirst report Oct 27 11:22 연합뉴스경제
4
에스티팜, 3분기 영업익 157억원…전년比 7%↑
2 outlets · 2 articlesFirst report Oct 27 11:29 디지털타임스Earnings
5
동아에스티·에스티팜, 3분기 나란히 성장…매출·영업익 동반 증가
2 outlets · 2 articlesFirst report Oct 27 15:01 조선비즈Dong-a ST
6
'HIV 신약' 성적표 받은 에스티팜 … 기술이전·원료공급 '두 마리' 토끼 잡을까
1 outlets · 1 articlesFirst report Oct 21 11:40 뉴데일리경제Licensing deal

Latest ST Pharm news Korean headlines

13:45

Major에스티팜, 올리고 수주 늘었지만···수익성 개선·신약 성과는 과제
서울파이낸스Order / supply contract
Oct 2917:34

Major에스티팜, 잇단 신규 수주 행보…"지속 성장 기회 마련돼"
머니투데이Order / supply contract
Oct 2913:40

Major에스티팜, 잇단 수주···신규 고객사 확보까지
시사저널eOrder / supply contract
Oct 2907:56

에스티팜 목표가 하향, 환율 하락·대규모 수주 부진-하나
PRESS9Order / supply contract
Oct 2817:19

에스티팜, 3분기 매출 976억원·영업이익 157억원
메디칼업저버
Oct 2811:22

LG이노텍, 셀트리온, HD현대일렉트릭, 한화오션, 에스티팜, 성광벤드 등
한국경제LG Innotek Sung Kwang Bend Hanwha Ocean Celltrion+1
Oct 2810:35

Major기대치 이하지만…에스티팜, '공장 풀가동' 턴어라운드
경제타임스Demand surge
Oct 2807:46

Major에스티팜 목표가 하향, 펠라카르센 임상 3상 실패 반영-KB證
PRESS9Clinical trial
Oct 2716:58

동아제약·동아ST·에스티팜, 3분기 매출·영업이익 동반 증가
뉴시안Dong-A Socio Holdings
Oct 2716:15

에스티팜, 3분기 매출 19.1% 성장... 순이익은 95% 급감
시장경제신문
Oct 2715:01

에스티팜, 3Q 매출 19.1% 증가…환손실에 순이익 위축
PRESS9Earnings
Oct 2715:01
동아에스티·에스티팜, 3분기 나란히 성장…매출·영업익 동반 증가
조선비즈Dong-a ST
1 more on this story · 1 outlets
- 동아에스티·에스티팜, 3분기 나란히 성장…매출·영업익 동반 증가조선일보 · Oct 27 15:09
Oct 2714:36

Major에스티팜, 올리고 상업화 수주 확대에 매출 19.1%↑
서울경제Order / supply contract
Oct 2714:32

에스티팜, 3분기 영업익 157억…전년비 6.6%↑
스마트비즈Earnings
Oct 2713:41

에스티팜, 3분기 매출 19% 증가한 976억원…CDMO 성장세 지속
리드경제Earnings
Oct 2713:18

MajorBreaking에스티팜, 3Q 영업익 6.57% 증가에도 순익 94.7% 급감
뉴데일리경제Earnings
Oct 2713:17

에스티팜, 3분기 매출 976억원... 당기순이익은 감소
디스커버리뉴스
Oct 2713:06

에스티팜, 상업화 품목 매출 확대 ‘순항’…3분기 매출 976억원·영업익 157억원
더바이오
Oct 2712:42

에스티팜 3분기 매출 976억 기염, 올리고 CDMO 성장 가속
에너지뉴스
Oct 2712:41

동아제약·동아ST·에스티팜, 3분기 동반 성장…주력사업 호조에 실적 개선
메디팜스투데이Dong-A Socio Holdings
Oct 2712:37
에스티팜, 3분기 매출 976억…전년比 19.1% 증가
뉴스1Earnings
2 more on this story · 2 outlets
- 에스티팜, 3분기 매출 976억…전년대비 19% 증가뉴시스경제 · Oct 27 14:29
- 에스티팜, 3분기 매출 19.1% 증가…순이익은 94.8% 감소푸드투데이 · Oct 27 17:38
Oct 2712:11
에스티팜, 3분기 매출 976억원…올리고 상업화 매출 성장 견인
메디파나뉴스
1 more on this story · 1 outlets
- 에스티팜, 3분기 매출 19% 증가…올리고 상업화가 성장 견인EBN · Oct 27 14:20
Oct 2712:01

[실적] 3Q '동아패밀리' 동아ST 27%, 동아제약 5%, 에스티팜 7% 끌어올려
히트뉴스Dong-A Socio Holdings
Oct 2711:48

Major에스티팜, 3분기 연결영업익 157억…전년比 6.6%↑
메디파나뉴스Earnings
Oct 2711:29
에스티팜, 3분기 영업익 157억원…전년比 7%↑
디지털타임스Earnings
1 more on this story · 1 outlets
- 에스티팜, 3분기 영업익 157억⋯전년 대비 6.6% 증가아이뉴스24 · Oct 27 14:29
Oct 2711:22
에스티팜 3분기 영업이익 157억원…작년 동기 대비 6.6%↑
연합뉴스경제
1 more on this story · 1 outlets
- 에스티팜, 3분기 영업이익 157억원…전년比 6.6%↑아시아경제 · Oct 27 13:36
Oct 2707:11

[오늘의 IR] 동아제약ㆍ한미약품ㆍ에스티팜 등
이투데이Dong-A Socio Holdings Hanmi Pharm
Oct 2308:15

[서치 e종목] 에스티팜, 4분기 상업화 올리고 매출 분기 최대 전망…주가 반등?
데일리인베스트
Oct 2306:00

Major로슈가 생산 설비 내주고 기술 전수까지…에스티팜, RNA 대형 수주 노린다
조선비즈Order / supply contract
Oct 2215:30

“RNA 신약 시장 커진다…에스티팜·올릭스·SK바이오팜 주목”
한국경제OliX Pharmaceuticals SK biopharmaceuticals

Articles per day 2 weeks

121

222

223

2527

428

329

130

Company profile

CEO: Sung Moo-je
Industry: Pharmaceuticals
Founded: 2008-08-18
Fiscal year-end: December
Head office: 경기도 시흥시
Website: stpharm.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

ST Pharm dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩500	0.3%	18.3%
FY2024	₩500	0.6%	30.8%
FY2023	₩500	0.8%	48.0%

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

동아쏘시오홀딩스37.67%
국민연금공단5.77%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	197
Kwangdong Pharmaceutical	₩2.8bn	188
JW Pharmaceutical	₩33.3bn	185

Compare ST Pharm side by side with these companies

ST Pharm DART filings

Oct 2713:21

Investor relations event 기업설명회(IR)개최
Other
Oct 2711:14

Preliminary earnings 연결재무제표기준영업(잠정)실적(공정공시)
Earnings & dividends
Oct 2216:24

Investor relations event 기업설명회(IR)개최
Other
Oct 2216:23

Other 결산실적공시예고
Other
Oct 813:46

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 614:37

Clinical trial 투자판단관련주요경영사항(임상시험결과) (HIV-1 치료제 STP0404 임상 2a상 임상시험결과보고서(CSR) 수령)
Clinical & patents
Oct 213:37

5% ownership report 주식등의대량보유상황보고서(약식)
Ownership reports
Sep 1814:26

Supply contract 단일판매ㆍ공급계약체결
Contracts & investment
Sep 915:38

Investor relations event 기업설명회(IR)개최
Other

Catalysts 2 weeks

Earnings12
Contracts & orders7
Tech & capacity2
Clinical & approvals1

Mentioned alongside 2 weeks

ST Pharm FAQ

Who is the CEO of ST Pharm?: According to the DART company overview, ST Pharm's representative director is Sung Moo-je (name as registered in Korean). The company was founded on 2008-08-18.
Where is ST Pharm listed?: ST Pharm trades on the Korea Exchange KOSDAQ market under the ticker 237690. Its fiscal year ends in December.
What were ST Pharm's latest quarterly results?: In Q2 2026, ST Pharm reported revenue of ₩108bn, up 58.9% year on year, and operating profit of ₩18.3bn. Figures come from reports filed on DART.
Does ST Pharm pay a dividend?: Yes. For fiscal 2025, ST Pharm paid a cash dividend of ₩500 per common share, a 0.3% yield as stated in its annual report, with a payout ratio of 18.3%. The prior year's dividend was ₩500.
Does ST Pharm have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Revenue +30% (latest quarterly revenue up more than 30% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); Clinical trial filing (filing on clinical trial plans or results (90 days)). These are factual flags, not investment advice.
Which companies are in the same industry as ST Pharm?: Under the Korean Standard Industrial Classification recorded on DART, ST Pharm is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.